Literature DB >> 20586803

Management of difficult-to-treat inhibitor patients.

P L F Giangrande1, M A Escobar.   

Abstract

The workshop looked at seven scenarios based on fictional and real-life cases of difficult-to-treat patients with haemophilia A or haemophilia B and inhibitors with the aim of sharing clinical opinion and experience from around the world. Delegate opinions on the best treatment option for each scenario are described together with actual treatment given in real-life cases and its outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20586803     DOI: 10.1111/j.1365-2516.2010.02261.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  2 in total

1.  Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.

Authors:  Q Shi; E L Kuether; J A Schroeder; C L Perry; S A Fahs; J Cox Gill; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

2.  Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity.

Authors:  Jocelyn A Schroeder; Juan Chen; Yingyu Chen; Yuanhua Cai; Hongyin Yu; Jeremy G Mattson; Paul E Monahan; Qizhen Shi
Journal:  Blood Adv       Date:  2021-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.